Post-MI Patient
After STEMI or NSTEMI
All Pathways
CardiologyManagement
Post-MI Secondary Prevention (ESC 2023)
Post-MI Secondary Prevention (ESC 2023): Post-MI Patient → Antithrombotic Therapy → Beta-Blocker → SGLT2 Inhibitor → ICD Evaluation.
Pathway Overview
10 steps
Algorithm Steps
10 total
01Start 02Action Antithrombotic Therapy
DAPT then maintenance
- DAPT x 12 months
- Aspirin + Ticagrelor/Prasugrel
- Then aspirin indefinitely
03Action Beta-Blocker
≥1 year, indefinite if HF
- Carvedilol, bisoprolol, metoprolol
- Indefinite if LVEF ≤40%
- Indefinite if arrhythmia/HF
04Action SGLT2 Inhibitor
If HFrEF/HFmrEF/DM/CKD
- Dapagliflozin or empagliflozin
- Growing evidence post-MI
05Warning ICD Evaluation
At ≥40 days post-MI
- If LVEF ≤35% despite OMT x 3mo
- Primary prevention SCD
06Outcome Lifelong Secondary Prevention
Regular follow-up, optimize GDMT
07Action Cardiac Rehabilitation
Class I recommendation
- Exercise training
- Risk factor education
- Psychosocial support
- Path rejoins step 06Shared downstream outcome
08Action Lipid Therapy
Aggressive LDL lowering
- Target: LDL <55 mg/dL + ≥50% reduction
- Recurrent event: <40 mg/dL
- Step 1: High-intensity statin
- Step 2: + Ezetimibe
- Step 3: + PCSK9i
09Action ACEi/ARB/ARNI
All post-STEMI patients
- Especially if LVEF ≤40%
- Anterior MI, HTN, DM
- ARNI if HF develops
- Path rejoins step 04Shared downstream outcome
10Action MRA
If LVEF ≤40% + symptoms/DM
- Spironolactone or eplerenone
- Monitor K+ and renal function
- Path rejoins step 04Shared downstream outcome
Guideline Source
ESC 2019 Dyslipidemia + ESC 2023 ACS Guidelines
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Drug dosing not included
- Cardiac rehab details simplified
- Does not address CABG-specific considerations
Contraindicated Populations
pediatric
Applicable Regions
EUUS
EU: ESC targets: LDL <55 mg/dL, <40 if recurrent
US: ACC/AHA similar but LDL targets may differ
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Post-MI Secondary Prevention (ESC 2023)?
The Post-MI Secondary Prevention (ESC 2023) is a management clinical algorithm for Cardiology. It provides a structured decision tree to guide clinical decision-making, based on ESC 2019 Dyslipidemia + ESC 2023 ACS Guidelines.
What guideline is the Post-MI Secondary Prevention (ESC 2023) based on?
This algorithm is based on ESC 2019 Dyslipidemia + ESC 2023 ACS Guidelines (DOI: 10.1093/eurheartj/ehz455).
What are the limitations of the Post-MI Secondary Prevention (ESC 2023)?
Known limitations include: Drug dosing not included; Cardiac rehab details simplified; Does not address CABG-specific considerations. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Post-MI Secondary Prevention (ESC 2023) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free